PROTAC AR degraders can induce proteasome-mediated degradation of AR protein in prostate cancer, block AR signaling and suppress the mRNA levels of AR-regulated genes, which results in cellular proliferation inhibition, induction of cell apoptosis, and antitumor activity in a xenograft model (Figure 5B). The gene discussed is AR; the disease is prostate carcinoma.